Get this domain name before someone else does. Quick and painless shopping. Affordable payment options available.
Location: United States
Total raised: $23M
Investors 1
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.08.2011 | Series B | $23M | - |
Mentions in press and media 9
| Date | Title | Description |
| 08.11.2012 | BSX’s $300M acquisition of Vessix Vascular shows continued consolidation in renal denervation | Boston Scientific (NYSE:BSX) is jumping on the renal denervation bandwagon. The Natick, Massachusetts, medical device manufacturer announced Thursday that it is buying Caifornia startup Vessix Vascular for an upfront payment of $125 million... |
| 30.05.2012 | Renal denervation by ultrasound may set apart Kona in hypertension market | An estimated 10 percent to 20 percent of the 78 million U.S. patients with hypertension don’t respond to blood pressure drugs. Ever since Ardian published positive clinical trial results using renal ablation and was promptly acquired by Med... |
| 08.05.2012 | Covidien discloses $60M purchase of hypertension treatment firm | In a note to investors Monday, analyst Bob Hopkins of Bank of America said that renal denervation “has the potential to be one of the largest new markets in medtech over the next 2-4 years and for [Covidien] this looks like another small de... |
| 03.08.2011 | Vessix Vascular Completes $23M Series B Financing | Vessix Vascular, Inc. (formerly known as Minnow Medical), a Laguna Hills, California-based developer of novel percutaneous radiofrequency (RF) balloon catheter technology, has completed a $23m Series B financing. The round was led by Edmond... |
| 03.08.2011 | USD 23 million financing complete and corporate name changed to Vessix Vascular | Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.), a developer of novel percutaneous radiofrequency (RF) balloon catheter technology announced today that it has completed a $23 million Series B preferred stock financing. The le... |
| 03.08.2011 | Vessix Vascular Completes $23 Million Financing | Round Led by Edmond de Rothschild Investment Partners and OrbiMed Advisors. >> Click here for more funding data on Vessix Vascular >> To export Vessix Vascular funding data to PDF and Excel, click here LAGUNA HILLS, CA, V... |
| - | Covidien discloses $60M purchase of hypertension treatment firm | Covidien announced Tuesday that it will introduce a new renal denervation treatment at a European conference in mid May, but nowhere in the press release does the Massachusetts device firm name the developer of the technology: Maya Medical,... |
| - | BSX’s $300M acquisition of Vessix Vascular shows continued consolidation in renal denervation | UPDATED WITH ANALYST COMMENT Boston Scientific (NYSE:BSX) is jumping on the renal denervation bandwagon. The Natick, Massachusetts, medical device manufacturer announced Thursday that it is buying Caifornia startup Vessix Vascular for an up... |
| - | Renal denervation by ultrasound may set apart Kona in hypertension market | The hypertension treatment market is hot, with Medtronic leading the way in commercializing a renal denervation device. An estimated two dozen other companies are chasing the medical device heavyweight using the same approach, and today ano... |